GP

Galmed Pharmaceuticals LtdFRA Galmed Stock Report

Last reporting period 30 Sep, 2023

Updated 28 Oct, 2024

Last price

Market cap $B

0.005

Micro

Exchange

XFRA - Deutsche Boerse AG

GPH.F Stock Analysis

GP

Uncovered

Galmed Pharmaceuticals Ltd is uncovered by Eyestock quantitative analysis.

Market cap $B

0.005

Dividend yield

Shares outstanding

25.203 B

Galmed Pharmaceuticals Ltd. is a clinical-stage drug development biopharmaceutical company, which engages in the development of oral therapy for the treatment of non-alcoholic steato-hepatitis (NASH). Arachmol, the main product of Galmed Pharmaceuticals, is a liver-targeted stearoyl-coenzyme A desaturase1 used in oral therapy for the treatment of NASH (Non-alcoholic Steatohepatitis).

View Section: Eyestock Rating